Seminars in Oncology Nursing
Volume 25, Issue 1 , Pages 32-47 , February 2009

Colon, Rectal, and Anal Cancers

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Saltz L. Management of metastatic colorectal cancer: the impact of clinical trials reported at ASCO 2007. Comm Oncol. 2008;5:37–42
  3. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13:51–56
  4. Headrick JR, Miller DL, Nagorney DM, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg. 2001;71:975–980
  5. American Cancer Society. Colorectal cancer facts and figures, special edition 2005. Atlanta, GA: American Cancer Society. Available at: http://www.cancer.org/docroot/STT/stt_0.asp (accessed March 27, 2008).
  6. Espy DK, Wu X-C, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska natives. Cancer. 2007;110:2119–2152
  7. O'Connell JB, Maggard MA, Ko Cy. Colon cancer survival rates with the new American Joint Committee on Cancer staging 6th ed. J Natl Cancer Inst. 2004;96:1420–1425
  8. In:  Greene FL,  Page DL,  Fleming ID editor. AJCC cancer staging manual. 6th ed. New York, NY: Springer-Verlag; 2002;
  9. Wei EK, Giovannucci E, Wu K, et al. Comparison of risk factors for colon and rectal cancer. Intl J Cancer. 2003;108:433–442
  10. Colditz GA, Atwood KA, Emmons K, et al. Harvard report on cancer prevention. Vol 4. Harvard Cancer Risk Index. Cancer Causes Control. 2000;11:477–488
  11. Luchtenborg M, Weijenberg MP, Kampman E, et al. Cigarette smoking and colorectal cancer: APC mutations, hMLH1 expression, and GSTM1 and GSTT1 polymorphisms. Am J Epidemiol. 2005;161:806–815
  12. Libutti SK, Saltz LB, Tepper JE. Colon cancer. In: De Vita VT, Lawrence TS, Rosenberg SA, Eds. 8th ed. Cancer Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins. pp. 1232-1285.
  13. Griffin-Sobel JP. Characteristics, pathophysiology, disease manifestations of colorectal cancer. In:  Berg DT editors. Contemporary issues in colorectal cancer: a nursing perspective. Sudbury MA: Jones and Bartlett; 2001;p. 53–65
  14. Levine JS, Ahnen DJ. Adenomatous polyps of the colon. N Engl J Med. 2006;355:2551–2557
  15. Kim DH, Pickhardt PJ, Taylor AJ, et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med. 2007;357:1403–1412
  16. Rudy DR, Zdon MJ. Update on colorectal cancer. Am Fam Phys. 2000;61:1759–1769
  17. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer. 2005;5:199–209
  18. Soetikno RM, Kaltenbach T, Rouse RV, et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA. 2008;299:1027–1035
  19. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA. 2003;289:1288–1296
  20. Levin B, Lieberman D, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:30–60
  21. Imperiale TF, Glowinski EA, Lin-Cooper C, et al. Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med. 2008;359:1218–1224
  22. Johnson CD, Chen MM, Toledano AY, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med. 2008;359:1207–1217
  23. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2008;
  24. Center for Disease Control. Use of colorectal cancer tests-United States, 2002, 2004, and 2006. MMWR Morbid Mortal Wkly Rep. 2008;57:253–258
  25. Parikh-Patel A, Bates JH, Campleman S. Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988-2000. Cancer. 2006;107(suppl 5):1189–1195
  26. Jackson-Thompson J, Ahmed F, German RR, et al. Descriptive epidemiology of colorectal cancer in the United States 1998-2001. Cancer. 2006;107(suppl 5):1103–1111
  27. Selzner M, Hany TF, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg. 2004;240:1027–1036
  28. National Comprehensive Cancer Network Clinical Practice Guidelines: Colon cancer v.1.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf (accessed March 27, 2008).
  29. National Comprehensive Cancer Network ClinicalPractice Guidelines: Rectal cancer v.1.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf (accessed March 27, 2008).
  30. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the Surveillance, Epidemiology an End Results Experience, 1973-2000. Cancer. 2004;101:281–288
  31. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000;342:792–800
  32. Panagiotis A, Konstantinopoulos HP, Schlecht BB, et al. HIV-associated anal squamous cell cancer: an otherwise preventable disease. J Clin Oncol. 2006;24:4516–4517
  33. National Comprehensive Cancer Network Clinical Practice Guidelines: Anal cancer. v.1 2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/anal.pdf (accessed March 27, 2008).
  34. New York State AIDS Malignancy Consortium. Criteria for the medical care of adults with HIV infection. New York State Department of Health AIDS Institute. March 2004;1–18
  35. Uronis HE, Bendell JC. Anal cancer: an overview. The Oncologist. 2007;12:524–534
  36. Eliashvili N, Landry J, Matthews RH. Carcinoma of the anus: strategies in management. The Oncologist. 2002;7:188–199
  37. Hoffman R, Welton ML, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44:127–131
  38. Myerson RJ, Karnell LH, Menck HR. The National Cancer Data Base report on carcinoma of the anus. Cancer. 1997;80:805–815
  39. Joseph NE, Sigurdson ER, Hanlon AH, et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003;10:213–218
  40. Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005;23:8706–8712
  41. Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006;24:3570–3575
  42. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted an open colectomy for colon cancer. N Engl J Med. 2004;240:2050–2059
  43. Benson AB. . Selection of patients with stage II disease for adjuvant therapy. Comm Oncol. 2007;4(Suppl 3):5–10
  44. Kopetz S, Freitas D, Calabrich AFC, Hoff PM. Adjuvant chemotherapy for stage II colon cancer. Oncology. 2008;22:260–270
  45. Burdy G, Panis Y, Alves A, et al. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum. 2001;44:1682–1688
  46. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395–3419
  47. Sargent DJ, Patiyil S, Yothers G, et al. End points of colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol. 2007;25:4569–4574
  48. Gray R, Barnwell J, Hills R. Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet. 2007;370:2020–2029
  49. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351
  50. de Gramont A, Boni C, Navarro J, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Proc Am Soc Clin Oncol. 2007;25:165S;(abstr 4007)
  51. Baddi L, Benson A. Adjuvant therapy in stage II colon cancer: current approaches. The Oncologist. 2005;10:325–331
  52. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies. J Clin Oncol. 1999;17:1349–1355
  53. Marsoni S. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol. 2001;28(Suppl 1):14–19
  54. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol. 2004;22:1797–1806
  55. Liver-Infusion Meta-Analysis Group . Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst. 1997;89:497–505
  56. Benson A III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. 2006. Available at: http://www.asco.org (accessed March 28, 2008).
  57. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite- instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–257
  58. Vicuna B, Benson AB. . Adjuvant therapy for stage II colon cancer: prognostic and predictive markers. J Natl Compr Cancer Net. 2007;5:927–936
  59. Johnston PG, Mulligan K, Kay E, et al. A genetic signature of relapse in stage II colorectal cancer derived from formalin fixed paraffin embedded tissue (FFPE) tissue using a unique disease specific colorectal array. [abstr 3519] J Clin Oncol. 2006;24(Suppl 1):150s
  60. deGramont A, Boni C, Navarro J, et al, Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow up of 4 years [abstr 167]. Hollywood, FL; 2005 ASCO Gastrointestinal Cancers Symposium Proceedings. 2005;1:167.
  61. Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. [abstr 3500] J Clin Oncol 2005 ASCO Annual Meeting Proceedings. 2005;23(June 1 suppl):246s
  62. Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol. 2003;14:1735–1743
  63. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-FU/LV in stage III colon cancer: updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy [abstr 274]. Orlando, FL: 2008 ASCO Gastrointestinal Cancers Symposium Proceedings. 2008;1:205.
  64. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  65. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  66. Beaty KA, Curley SA. Metastectomy for combined hepatic and extrahepatic colorectal cancer metastases. Curr Colorec Cancer Rep. 2007;3:89–93
  67. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal (liver) metastases. Ann Surg Oncol. 2001;8:347–353
  68. Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified?. Ann Surg. 2004;239:722–732
  69. Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on respectability of hepatic colorectal metastases. J Am Coll Surg. 2005;5:845–853
  70. Michael M, Van Cutsem E, Kretzschmar A, et al. Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - Preliminary results from the First Beat study [abstr 3523]. J Clin Oncol. 2006;ASCO Annual Meeting Proceedings. Part I. 2006;24(June 20 suppl):151s
  71. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23:7125–7134
  72. Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. [abstr LBA5] J Clin Oncol 2007 ASCO Annual Meeting Proceedings. Part I. 2007;25(June 20 suppl):2s
  73. Julic C, Lutz MP, Aust D, et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983 [abstr 241]. Orlando, FL: 2007 ASCO Gastrointestinal Cancers Symposium Proceedings. 2007;1:205.
  74. Fuchs CS, Marshall J, Mitchell EP, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations +/-celecoxib in mCRC: clinical data cut-off September 1, 2006 [abstr 276]. Orlando, FL: 2007 ASCO Gastrointestinal Cancers Symposium Proceedings. 2007;1:222.
  75. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–237
  76. Cassidy J, Clarke S, Diaz-Rubio E, et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer [abstr 341]. Orlando, FL: 2008 ASCO Gastrointestinal Cancers Symposium Proceedings. 2008;1:239.
  77. Grothey A, Hedrick EE, Maas RD, et al. Response independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107g. J Clin Oncol. 2008;26:183–189
  78. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706–3712
  79. Hochster H, Hart LL, Ramanathan R, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26:3523–3529
  80. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–2048
  81. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–1664
  82. Hecht JR, Mitchell E, Chidiac T, et al. Interim results from PACCE: irinotecan (Iri)/bevacizumab (bev) +/- panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC) [abstr 279]. Orlando, FL: 2008 ASCO Gastrointestinal Cancers Symposium Proceedings. 2008;1:208
  83. Lievre A, Bachet J-B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995
  84. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–1634
  85. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer. J Clin Oncol. 2006;24:394–400
  86. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MCRC): a GERCOR study [abstr 4013]. J Clin Oncol 2007 ASCO Annual Meeting Proceedings. Part I. 2007;25(June 20 suppl):166s
  87. Fleshner PR, Chalasani S, Chang GJ, et al. Practic parameters for anal squamous neoplasms. Dis Colon Rectum. 2008;51:2–9
  88. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–2539
  89. Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17:354–356
  90. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal. JAMA. 2008;299:1914–1921
  91. Meropol NJ, Niedzwiecki D, Shank B, et al. Induction therapy for poor-prognosis anal can carcinoma: a phase II study of the cancer and leukemia Group B (CALGB 9281). J Clin Oncol. 2008;28:3229–3234
  92. George TJ. KRAS mutational analysis: ready for prime time?. Comm Oncol. 2008;5:435–436

PII: S0749-2081(08)00074-0

doi: 10.1016/j.soncn.2008.10.003

Seminars in Oncology Nursing
Volume 25, Issue 1 , Pages 32-47 , February 2009

Article Tools